CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, today announced that an oral presentation on its lead drug candidate, BIND-014, has been selected to be presented at the American Association for Cancer Research (AACR) 2013 Annual Meeting taking place April 6-10, 2013 in Washington, DC. The presentation will describe the results of a phase 1 study of BIND-014 in patients with advanced or metastatic solid tumors.
BIND-014 is the first targeted and programmable nanomedicine to enter human clinical studies. In preclinical studies, BIND-014 has demonstrated both targeting and an improved pharmacologic profile resulting in high tumor drug concentrations and tumor growth inhibition for an extended period of time compared to the equivalent conventionally formulated docetaxel.
Details on the oral presentation of BIND-014 at AACR:
- (Abstract #LB203): Tuesday, April 9, 2013, 2:30 PM - 3:50 PM, “A Phase 1 Study of BIND-014, a PSMA-targeted Nanoparticle Containing Docetaxel, in Patients with Refractory Solid Tumors,” Daniel D. Von Hoff, M.D., TGen (Translational Genomics Research Institute),Clinical Trials Symposium 3: Clinical Pharmacology of Novel Agents in Solid Tumors, Room 146 in The Washington Convention Center.
About Accurins™
BIND Biosciences is discovering and developing Accurins, proprietary new best-in-class therapeutics which have demonstrated superior target selectivity and programmable properties in preclinical studies, offering the potential to improve patient outcomes. Leveraging its proprietary Medicinal Nanoengineering® platform, BIND develops Accurins that are designed to outperform conventional drugs by selectively accumulating in diseased tissues and cells. The objective is to provide higher drug concentrations at the site of action with minimal off-target exposure, and the potential to improve efficacy and safety. In addition to target selectivity, the programmable properties of Accurins allow for fine-tuning the pharmacokinetic and biodistribution of drugs, differentiating characteristics which have been demonstrated in preclinical studies.
About BIND Biosciences
BIND Biosciences is a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM. BIND’s Medicinal Nanoengineering® platform enables the design, engineering and manufacturing of Accurins with unprecedented control over drug properties to maximize trafficking to disease sites, with the objective of enhancing efficacy while minimizing toxicities.
BIND is developing a pipeline of novel Accurins that hold extraordinary potential to become best-in-class drugs and improve patient outcomes. BIND's lead product candidate, BIND-014, is currently entering Phase 2 clinical testing in cancer patients and is designed to selectively target PSMA, a surface protein upregulated in a broad range of solid tumors. BIND also develops Accurins in collaboration with pharmaceutical and biotechnology partners to enable promising pipeline candidates to achieve their full potential and to utilize selective targeting to transform the performance of important existing drug products.
BIND is backed by leading investors, Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano. BIND was founded on proprietary technology from the laboratories of two leaders in the field of nanomedicine, Professors Robert Langer, David H. Koch Institute Professor of the Massachusetts Institute of Technology (MIT) and Omid Farokhzad, Associate Professor of Harvard Medical School. For more information, please visit the company's web site at www.bindbio.com.